CO6321252A2 - Derivados de quinoxalindiona - Google Patents
Derivados de quinoxalindionaInfo
- Publication number
- CO6321252A2 CO6321252A2 CO10156748A CO10156748A CO6321252A2 CO 6321252 A2 CO6321252 A2 CO 6321252A2 CO 10156748 A CO10156748 A CO 10156748A CO 10156748 A CO10156748 A CO 10156748A CO 6321252 A2 CO6321252 A2 CO 6321252A2
- Authority
- CO
- Colombia
- Prior art keywords
- quinoxalindiona
- derivatives
- obesity
- diabetes
- inflammation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (I)en la que X, Y, Z, R1, R2, R3 son como se definen en la reivindicación 1, incluyendo sus composiciones farmacéuticas y su uso en el tratamiento y/o la prevención de diabetes, síndrome metabólico, obesidad, cáncer, inflamación.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290564 | 2008-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6321252A2 true CO6321252A2 (es) | 2011-09-20 |
Family
ID=40823394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10156748A CO6321252A2 (es) | 2008-06-16 | 2010-12-14 | Derivados de quinoxalindiona |
Country Status (25)
Country | Link |
---|---|
US (2) | US8329698B2 (es) |
EP (1) | EP2285786B1 (es) |
JP (1) | JP5596676B2 (es) |
KR (1) | KR101641391B1 (es) |
CN (1) | CN102066342B (es) |
AR (1) | AR072148A1 (es) |
AU (1) | AU2009259754B2 (es) |
BR (1) | BRPI0915064B8 (es) |
CA (1) | CA2728018C (es) |
CO (1) | CO6321252A2 (es) |
CY (1) | CY1114737T1 (es) |
DK (1) | DK2285786T3 (es) |
EA (1) | EA020236B1 (es) |
EC (1) | ECSP11010760A (es) |
ES (1) | ES2436195T3 (es) |
HK (1) | HK1157784A1 (es) |
HR (1) | HRP20131069T1 (es) |
IL (1) | IL209421A (es) |
MX (1) | MX2010013577A (es) |
MY (1) | MY155695A (es) |
NZ (1) | NZ590503A (es) |
PL (1) | PL2285786T3 (es) |
PT (1) | PT2285786E (es) |
SI (1) | SI2285786T1 (es) |
WO (1) | WO2009152909A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
MX371331B (es) | 2012-04-24 | 2020-01-27 | Vertex Pharma | Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk). |
KR102216284B1 (ko) | 2013-03-12 | 2021-02-18 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제 |
CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
CN103435561B (zh) * | 2013-08-19 | 2016-08-10 | 上海交通大学 | 一种新型d-氨基酸氧化酶抑制剂及其制备和应用 |
RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
EP3941496A4 (en) * | 2019-03-18 | 2022-11-23 | University of Washington | METHOD OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORS |
CN110642798B (zh) * | 2019-11-10 | 2020-07-24 | 湖南科技学院 | 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法 |
IL298306A (en) | 2020-05-19 | 2023-01-01 | Kallyope Inc | ampk operators |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
JP2023544026A (ja) | 2020-09-30 | 2023-10-19 | バイオベラティブ セラピューティクス インコーポレイテッド | Ampk活性化因子及びその使用方法 |
US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
EP4249489A4 (en) * | 2020-11-26 | 2023-10-18 | Lg Chem, Ltd. | HETEROCYCLIC COMPOUND AS A DIACYLGLYCEROLKINASE INHIBITOR AND USE THEREOF |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
JP2001511805A (ja) | 1997-02-18 | 2001-08-14 | アメリカン・ホーム・プロダクツ・コーポレイション | ドパミン作動薬である5−アミノアルコキシ−1,4−ジヒドロキノキサリン−2,3−ジオン |
WO2002096422A2 (en) * | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways |
DE602004007693T2 (de) * | 2004-01-06 | 2008-06-05 | Janssen Pharmaceutica N.V. | (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas |
MY139645A (en) * | 2004-02-11 | 2009-10-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
MX2008014618A (es) * | 2006-05-15 | 2008-11-28 | Irm Llc | Composiciones y metodos para inhibidores de cinasas del receptor fgf. |
FR2903695B1 (fr) * | 2006-07-13 | 2008-10-24 | Merck Sante Soc Par Actions Si | Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2009
- 2009-05-19 WO PCT/EP2009/003538 patent/WO2009152909A1/en active Application Filing
- 2009-05-19 KR KR1020117000992A patent/KR101641391B1/ko active IP Right Grant
- 2009-05-19 SI SI200930812T patent/SI2285786T1/sl unknown
- 2009-05-19 PL PL09765489T patent/PL2285786T3/pl unknown
- 2009-05-19 CN CN2009801227397A patent/CN102066342B/zh active Active
- 2009-05-19 BR BRPI0915064A patent/BRPI0915064B8/pt active IP Right Grant
- 2009-05-19 US US12/997,641 patent/US8329698B2/en active Active
- 2009-05-19 DK DK09765489.1T patent/DK2285786T3/da active
- 2009-05-19 EP EP09765489.1A patent/EP2285786B1/en active Active
- 2009-05-19 CA CA2728018A patent/CA2728018C/en active Active
- 2009-05-19 PT PT97654891T patent/PT2285786E/pt unknown
- 2009-05-19 JP JP2011513895A patent/JP5596676B2/ja active Active
- 2009-05-19 MX MX2010013577A patent/MX2010013577A/es active IP Right Grant
- 2009-05-19 NZ NZ590503A patent/NZ590503A/xx unknown
- 2009-05-19 MY MYPI2010005917A patent/MY155695A/en unknown
- 2009-05-19 ES ES09765489T patent/ES2436195T3/es active Active
- 2009-05-19 AU AU2009259754A patent/AU2009259754B2/en active Active
- 2009-05-19 EA EA201100007A patent/EA020236B1/ru not_active IP Right Cessation
- 2009-06-16 AR ARP090102166A patent/AR072148A1/es active IP Right Grant
-
2010
- 2010-11-18 IL IL209421A patent/IL209421A/en active IP Right Grant
- 2010-12-14 CO CO10156748A patent/CO6321252A2/es active IP Right Grant
-
2011
- 2011-01-14 EC EC2011010760A patent/ECSP11010760A/es unknown
- 2011-11-16 HK HK11112373.9A patent/HK1157784A1/xx unknown
-
2012
- 2012-08-24 US US13/593,722 patent/US8674097B2/en active Active
-
2013
- 2013-11-08 HR HRP20131069AT patent/HRP20131069T1/hr unknown
- 2013-12-27 CY CY20131101166T patent/CY1114737T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP11010760A (es) | Derivados de quinoxalindiona | |
ECSP109903A (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
CR11861A (es) | Compuestos organicos | |
HN2009000784A (es) | Dihidropirazolonas sustituidas | |
UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
PA8809001A1 (es) | Compuestos organicos | |
BRPI0915084B8 (pt) | composto, e, composição farmacêutica | |
UY32543A (es) | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos | |
CL2011001082A1 (es) | Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2. | |
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CY1113435T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο | |
GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
CR20110318A (es) | Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos | |
CR11251A (es) | Depsipeptidos ciclicos y usos de los mismos | |
UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
CU20100111A7 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares | |
DOP2010000329A (es) | Inhibidores de la renina | |
ECSP109961A (es) | Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica | |
CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
BRPI0815455C1 (pt) | compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo | |
DOP2009000214A (es) | Macrolidos basados en eritromicina | |
CR11449A (es) | Productos intermedios gsm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |